407 related articles for article (PubMed ID: 24104591)
1. [Chronic lymphocytic leukemia].
Maurer C; Hallek M
Dtsch Med Wochenschr; 2013 Oct; 138(42):2153-66. PubMed ID: 24104591
[TBL] [Abstract][Full Text] [Related]
2. [Chronic lymphatic leukemia].
Bergmann M; Wendtner CM
Dtsch Med Wochenschr; 2015 Apr; 140(7):479-82. PubMed ID: 25826029
[TBL] [Abstract][Full Text] [Related]
3. Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment.
Hallek M
Am J Hematol; 2013 Sep; 88(9):803-16. PubMed ID: 23720127
[TBL] [Abstract][Full Text] [Related]
4. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.
Hallek M
Am J Hematol; 2015 May; 90(5):446-60. PubMed ID: 25908509
[TBL] [Abstract][Full Text] [Related]
5. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
Dennie TW; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
[TBL] [Abstract][Full Text] [Related]
6. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.
Hallek M
Am J Hematol; 2019 Nov; 94(11):1266-1287. PubMed ID: 31364186
[TBL] [Abstract][Full Text] [Related]
7. Watch and Wait in Lebanese Chronic Lymphocytic Leukemia Patients: How Relevant is it?
Lutfallah AA; Kourie HR; Eid R; Farhat F; Ghosn M; Kattan J
Asian Pac J Cancer Prev; 2016; 17(1):215-7. PubMed ID: 26838212
[TBL] [Abstract][Full Text] [Related]
8. [Chronic lymphocytic leukemia--the old and the new].
Korte W; Cogliatti S
Ther Umsch; 2004 Feb; 61(2):151-6. PubMed ID: 15018398
[TBL] [Abstract][Full Text] [Related]
9. The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia.
Visco C; Finotto S; Pomponi F; Sartori R; Laveder F; Trentin L; Paolini R; Di Bona E; Ruggeri M; Rodeghiero F
Am J Hematol; 2013 Apr; 88(4):289-93. PubMed ID: 23450436
[TBL] [Abstract][Full Text] [Related]
10. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.
Hallek M
Am J Hematol; 2017 Sep; 92(9):946-965. PubMed ID: 28782884
[TBL] [Abstract][Full Text] [Related]
11. [Chronic lymphatic leukemia].
Lechner K; Bilbeisi S; Wittmann E; Wilfing A
Wien Klin Wochenschr; 1994; 106(10):291-9. PubMed ID: 8053196
[TBL] [Abstract][Full Text] [Related]
12. Chronic lymphocytic leukemia.
Keating MJ
Semin Oncol; 1999 Oct; 26(5 Suppl 14):107-14. PubMed ID: 10561025
[TBL] [Abstract][Full Text] [Related]
13. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.
Sánchez ML; Almeida J; Vidriales B; López-Berges MC; García-Marcos MA; Moro MJ; Corrales A; Calmuntia MJ; San Miguel JF; Orfao A
Leukemia; 2002 Aug; 16(8):1460-9. PubMed ID: 12145686
[TBL] [Abstract][Full Text] [Related]
14. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
Keating MJ; O'Brien S; Albitar M; Lerner S; Plunkett W; Giles F; Andreeff M; Cortes J; Faderl S; Thomas D; Koller C; Wierda W; Detry MA; Lynn A; Kantarjian H
J Clin Oncol; 2005 Jun; 23(18):4079-88. PubMed ID: 15767648
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia.
Chow KU; Kim SZ; von Neuhoff N; Schlegelberger B; Stilgenbauer S; Wunderle L; Cordes HJ; Bergmann L
Eur J Haematol; 2011 Nov; 87(5):426-33. PubMed ID: 21749447
[TBL] [Abstract][Full Text] [Related]
16. [Clinical and laboratory prognostic parameters for leukemic types of chronic lymphoproliferative diseases].
Kardum-Skelin I; Planinc-Peraica A; Ostojić Kolonić S; Radić-Kristo D; Milas M; Vrhovac R; Sustercić D; Minigo H; Jaksić B
Acta Med Croatica; 2008 Oct; 62(4):351-64. PubMed ID: 19205412
[TBL] [Abstract][Full Text] [Related]
17. Pitting new treatments for chronic lymphocytic leukemia against old ones: how do they fare?
Shvidel L; Berrebi A
Expert Rev Hematol; 2016 Mar; 9(3):245-54. PubMed ID: 26613391
[TBL] [Abstract][Full Text] [Related]
18. Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: long-term prospective multicenter study.
Michallet M; Socié G; Mohty M; Sobh M; Bay JO; Morisset S; Labussière-Wallet H; Tabrizi R; Milpied N; Bordigoni P; El-Cheikh J; Blaise D
Exp Hematol; 2013 Feb; 41(2):127-33. PubMed ID: 23089183
[TBL] [Abstract][Full Text] [Related]
19. Management of chronic lymphocytic leukaemia.
Kalil N; Cheson BD
Drugs Aging; 2000 Jan; 16(1):9-27. PubMed ID: 10733261
[TBL] [Abstract][Full Text] [Related]
20. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
Robak T; Dmoszynska A; Solal-Céligny P; Warzocha K; Loscertales J; Catalano J; Afanasiev BV; Larratt L; Geisler CH; Montillo M; Zyuzgin I; Ganly PS; Dartigeas C; Rosta A; Maurer J; Mendila M; Saville MW; Valente N; Wenger MK; Moiseev SI
J Clin Oncol; 2010 Apr; 28(10):1756-65. PubMed ID: 20194844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
